|
000
| 01669nam 2200361zi 4500 |
|---|
| 001 | 9.865274 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107161747 |
|---|
| 006 | m o d f |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 181127s2019 onc o f000 0 eng d |
|---|
| 020 | |a9780660287041 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH164-255/2019E-PDF |
|---|
| 245 | 00|aFormat and content for post-market drug benefit-risk assessment in Canada. |
|---|
| 264 | 1|aOttawa : |bHealth Canada, |c2019. |
|---|
| 264 | 4|c©2019 |
|---|
| 300 | |a1 online resource (iii, 15 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Format et contenu des évaluations des avantages et des risques après la mise en marché au Canada. |
|---|
| 500 | |a"Guidance document." |
|---|
| 500 | |aIssued also in HTML format. |
|---|
| 504 | |aIncludes references. |
|---|
| 520 | |a"The objective of this guidance document is to assist Market Authorization Holders (MAHs) in developing a post-market benefit-risk assessment for a marketed drug when requested"--Objective, page 1. |
|---|
| 692 | 07|2gccst|aDrugs |
|---|
| 710 | 1 |aCanada. |bHealth Canada. |
|---|
| 775 | 08|tFormat et contenu des évaluations des avantages et des risques après la mise en marché au Canada |w(CaOODSP)9.865275 |
|---|
| 856 | 40|qPDF|s394 KB|uhttps://publications.gc.ca/collections/collection_2019/sc-hc/H164-255-2019-eng.pdf |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/publications/drugs-health-products/content-drug-benefit-risk-assessment/guidance-document.html |
|---|